Lung infections in cystic fibrosis

deriving clinical insight from microbial complexity

Geraint B Rogers, Franziska A Stressmann, Alan W Walker, Mary P Carroll, Kenneth D Bruce

Research output: Contribution to journalLiterature review

30 Citations (Scopus)

Abstract

Lower respiratory tract bacterial infections, such as those associated with cystic fibrosis lung disease, represent a major healthcare burden. Treatment strategies are currently informed by culture-based routine diagnostics whose limitations, including an inability to isolate all potentially clinically significant bacterial species present in a sample, are well documented. Some advances have resulted from the introduction of culture-independent molecular assays for the detection of specific pathogens. However, the application of bacterial community profiling techniques to the characterization of these infections has revealed much higher levels of microbial diversity than previously recognized. These findings are leading to a fundamental shift in the way such infections are considered. Increasingly, polymicrobial infections are being viewed as complex communities of interacting organisms, with dynamic processes key to their pathogenicity. Such a model requires an analytical strategy that provides insight into the interactions of all members of the infective community. The rapid advance in sequencing technology, along with protocols that limit analysis to viable bacterial cells, are for the first time providing an opportunity to gain such insight.
Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume10
Issue number2
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Cystic Fibrosis
Lung
Infection
Coinfection
Bacterial Infections
Respiratory Tract Infections
Lung Diseases
Virulence
Technology
Delivery of Health Care

Keywords

  • anti-bacterial agents
  • bacteria
  • cystic fibrosis
  • humans
  • lung diseases

Cite this

Lung infections in cystic fibrosis : deriving clinical insight from microbial complexity. / Rogers, Geraint B; Stressmann, Franziska A; Walker, Alan W; Carroll, Mary P; Bruce, Kenneth D.

In: Expert Review of Molecular Diagnostics, Vol. 10, No. 2, 03.2010, p. 187-196.

Research output: Contribution to journalLiterature review

Rogers, Geraint B ; Stressmann, Franziska A ; Walker, Alan W ; Carroll, Mary P ; Bruce, Kenneth D. / Lung infections in cystic fibrosis : deriving clinical insight from microbial complexity. In: Expert Review of Molecular Diagnostics. 2010 ; Vol. 10, No. 2. pp. 187-196.
@article{d048569078a24e1c986042af7f807343,
title = "Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity",
abstract = "Lower respiratory tract bacterial infections, such as those associated with cystic fibrosis lung disease, represent a major healthcare burden. Treatment strategies are currently informed by culture-based routine diagnostics whose limitations, including an inability to isolate all potentially clinically significant bacterial species present in a sample, are well documented. Some advances have resulted from the introduction of culture-independent molecular assays for the detection of specific pathogens. However, the application of bacterial community profiling techniques to the characterization of these infections has revealed much higher levels of microbial diversity than previously recognized. These findings are leading to a fundamental shift in the way such infections are considered. Increasingly, polymicrobial infections are being viewed as complex communities of interacting organisms, with dynamic processes key to their pathogenicity. Such a model requires an analytical strategy that provides insight into the interactions of all members of the infective community. The rapid advance in sequencing technology, along with protocols that limit analysis to viable bacterial cells, are for the first time providing an opportunity to gain such insight.",
keywords = "anti-bacterial agents, bacteria, cystic fibrosis, humans, lung diseases",
author = "Rogers, {Geraint B} and Stressmann, {Franziska A} and Walker, {Alan W} and Carroll, {Mary P} and Bruce, {Kenneth D}",
year = "2010",
month = "3",
doi = "10.1586/erm.09.81",
language = "English",
volume = "10",
pages = "187--196",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Lung infections in cystic fibrosis

T2 - deriving clinical insight from microbial complexity

AU - Rogers, Geraint B

AU - Stressmann, Franziska A

AU - Walker, Alan W

AU - Carroll, Mary P

AU - Bruce, Kenneth D

PY - 2010/3

Y1 - 2010/3

N2 - Lower respiratory tract bacterial infections, such as those associated with cystic fibrosis lung disease, represent a major healthcare burden. Treatment strategies are currently informed by culture-based routine diagnostics whose limitations, including an inability to isolate all potentially clinically significant bacterial species present in a sample, are well documented. Some advances have resulted from the introduction of culture-independent molecular assays for the detection of specific pathogens. However, the application of bacterial community profiling techniques to the characterization of these infections has revealed much higher levels of microbial diversity than previously recognized. These findings are leading to a fundamental shift in the way such infections are considered. Increasingly, polymicrobial infections are being viewed as complex communities of interacting organisms, with dynamic processes key to their pathogenicity. Such a model requires an analytical strategy that provides insight into the interactions of all members of the infective community. The rapid advance in sequencing technology, along with protocols that limit analysis to viable bacterial cells, are for the first time providing an opportunity to gain such insight.

AB - Lower respiratory tract bacterial infections, such as those associated with cystic fibrosis lung disease, represent a major healthcare burden. Treatment strategies are currently informed by culture-based routine diagnostics whose limitations, including an inability to isolate all potentially clinically significant bacterial species present in a sample, are well documented. Some advances have resulted from the introduction of culture-independent molecular assays for the detection of specific pathogens. However, the application of bacterial community profiling techniques to the characterization of these infections has revealed much higher levels of microbial diversity than previously recognized. These findings are leading to a fundamental shift in the way such infections are considered. Increasingly, polymicrobial infections are being viewed as complex communities of interacting organisms, with dynamic processes key to their pathogenicity. Such a model requires an analytical strategy that provides insight into the interactions of all members of the infective community. The rapid advance in sequencing technology, along with protocols that limit analysis to viable bacterial cells, are for the first time providing an opportunity to gain such insight.

KW - anti-bacterial agents

KW - bacteria

KW - cystic fibrosis

KW - humans

KW - lung diseases

U2 - 10.1586/erm.09.81

DO - 10.1586/erm.09.81

M3 - Literature review

VL - 10

SP - 187

EP - 196

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -